Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study

Atherosclerosis

Volumn 206, Issue 2, 2009, Pages 551-555

  Kinlay, Scott ^a,b   Schwartz, Gregory G ^c   Olsson, Anders G ^d   Rifai, Nader ^e   Bao, Weihang ^f   Libby, Peter ^b   Ganz, Peter ^g  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d LINKÖPING UNIVERSITY   (Sweden)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f PFIZER INC   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute coronary syndromes; Biomarkers; D dimer; Fibrinolysis; Outcomes; Risk; Tissue plasminogen activator

Indexed keywords

ATORVASTATIN; D DIMER; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SMOKING;

ACUTE CORONARY SYNDROME; AGED; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES; RECURRENCE; RISK; TISSUE PLASMINOGEN ACTIVATOR;

EID: 70349435467     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.03.020     Document Type: Article

References (35)

1. Wiman B., and Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost 16 (1990) 207-216
2. Lijnen H.R., and Coilen D. Endothelium in hemostasis and thrombosis. Prog Cardiovasc Dis 34 (1997) 343-350
3. Galvani M., Ferrini D., Ottani F., and Eisenberg P.R. Early risk stratification of unstable angina/non-Q myocardial infarction: biochemical markers of coronary thrombosis. Int J Cardiol 68 Suppl 1 (1999) S55-61
4. Jansson J.H., Nilsson T.K., and Olofsson B.O. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 12 (1991) 157-161
5. Jansson J.H., Olofsson B.O., and Nilsson T.K. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 88 (1993) 2030-2034
6. Niessner A., Graf S., Nikfardjam M., et al. Circulating t-PA antigen predicts major adverse coronary events in patients with stable coronary artery disease-a 13-year follow-up. Thromb Haemost 90 (2003) 344-350
7. Thompson S.G., Kienast J., Pyke S.D., Haverkate F., and van de Loo J.C. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 332 (1995) 635-641
8. Folsom A.R., Aleksic N., Park E., et al. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol 21 (2001) 611-617
9. Lowe G.D., Danesh J., Lewington S., et al. Tissue plasminogen activator antigen and coronary heart disease. Prospective study and meta-analysis. Eur Heart J 25 (2004) 252-259
10. Pradhan A.D., LaCroix A.Z., Langer R.D., et al. Tissue plasminogen activator antigen and D-dimer as markers for atherothrombotic risk among healthy postmenopausal women. Circulation 110 (2004) 292-300
11. Ridker P.M., Vaughan D.E., Stampfer M.J., Manson J.E., and Hennekens C.H. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 341 (1993) 1165-1168
12. Smith A., Patterson C., Yarnell J., et al. Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation 112 (2005) 3080-3087
13. Thogersen A.M., Jansson J.H., Boman K., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98 (1998) 2241-2247
14. Tzoulaki I., Murray G.D., Lee A.J., et al. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation 115 (2007) 2119-2127
15. Chandler W.L., Alessi M.C., Aillaud M.F., et al. Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 96 (1997) 761-768
16. Hamsten A., Wiman B., de Faire U., and Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313 (1985) 1557-1563
17. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
18. Kinlay S., Schwartz G.G., Olsson A.G., et al. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 110 (2004) 386-391
19. Kinlay S., Schwartz G.G., Olsson A.G., et al. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 108 (2003) 1560-1566
20. Cigolini M., Tonoli M., Borgato L., et al. Expression of plasminogen activator inhibitor-1 in human adipose tissue: a role for TNF-alpha?. Atherosclerosis 143 (1999) 81-90
21. Sundell I.B., Nilsson T.K., Ranby M., Hallmans G., and Hellsten G. Fibrinolytic variables are related to age, sex, blood pressure, and body build measurements: a cross-sectional study in Norsjo, Sweden. J Clin Epidemiol 42 (1989) 719-723
22. Smith D.T., Hoetzer G.L., Greiner J.J., Stauffer B.L., and DeSouza C.A. Effects of ageing and regular aerobic exercise on endothelial fibrinolytic capacity in humans. J Physiol 546 (2003) 289-298
23. Lindahl B., Nilsson T.K., Jansson J.H., Asplund K., and Hallmans G. Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance. J Intern Med 246 (1999) 105-112
24. Folsom A.R., Qamhieh H.T., Wing R.R., et al. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler Thromb 13 (1993) 162-169
25. Brugger-Andersen T., Hetland O., Ponitz V., Grundt H., and Nilsen D.W. The effect of primary percutaneous coronary intervention as compared to tenecteplase on myeloperoxidase, pregnancy-associated plasma protein A, soluble fibrin and D-dimer in acute myocardial infarction. Thromb Res 119 (2007) 415-421
26. Mak K.H., Lee L.H., Wong A., et al. Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction. Am J Cardiol 89 (2002) 930-936
27. Balk E.M., Lau J., Goudas L.C., et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 139 (2003) 670-682
28. Pokrovskaia E.V., Gratsianskii N.A., Averkov O.V., et al. Non ST elevation acute coronary syndrome: early use of pravastatin or atorvastatin is associated with divergent changes of parameters of hemostasis. Kardiologiia 43 (2003) 4-13
29. Bolaman Z., Kadikoylu G., Ozgel N., and Yenisey C. Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia. J Natl Med Assoc 98 (2006) 1273-1277
30. Chang J.W., Yang W.S., Min W.K., et al. Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. Am J Kidney Dis 39 (2002) 1213-1217
31. Dangas G., Badimon J.J., Smith D.A., et al. Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. J Am Coll Cardiol 33 (1999) 1294-1304
32. Joukhadar C., Klein N., Prinz M., et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 85 (2001) 47-51
33. Seljeflot I., Tonstad S., Hjermann I., and Arnesen H. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease. Thromb Res 105 (2002) 285-290
34. Sommeijer D.W., MacGillavry M.R., Meijers J.C., et al. Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. Diabetes Care 27 (2004) 468-473
35. Van De Ree M.A., De Maat M.P., Kluft C., et al. Decrease of hemostatic cardiovascular risk factors by aggressive versus conventional atorvastatin treatment in patients with type 2 diabetes mellitus. J Thromb Haemost 1 (2003) 1753-1757